📰 ReutersReutersCodex · 实盘不做把握 6/10
北京时间·🕒 发布 19:33:00时区推断·⟳ 抓取 19:34:27·⚡ 决策 08-03 19:51:44 +17m17s·85.1 天前
Supernus与Indivior达成全股票合并并计划10亿美元特别股息
合并后公司预计年收入约22亿美元，并称可实现约1.25亿美元年度成本节约。
📄 原文Reuters↗ 原文
Supernus Pharmaceuticals (SUPN.O) and Indivior Pharmaceuticals (INDV.O) said on Monday they had agreed to an all-stock…
不做 Supernus制药（SUPN.US）
并购利好已在盘前大幅反应，且换股加除息结构复杂，普通方向多头无清晰剩余edge。
不做 INDIVIOR（INDV.US）
特别股息伴随新增债务和合并审批，股价盘前已反应，当前不做方向单。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- Reuters报道Supernus与Indivior已同意全股票合并，并披露换股比例、股息、协同和预计四季度完成。市场反应:报道称SUPN盘前涨超20%、INDV盘前涨近10%。
关键理由
- 合并后公司预计年收入约22亿美元，并称可实现约1.25亿美元年度成本节约。
- 交易为1股SUPN换1.5401股INDV，INDV股东另获10亿美元特别现金股息，其中6.5亿美元拟由新债融资，套利口径受除息、审批和收盘期影响。
主要风险
- Reuters称SUPN盘前涨超20%、INDV涨近10%，但交易要到2026年四季度并需股东和监管批准，普通方向单容易变成追涨或复杂并购套利。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部库未命中独立增量研究；原文自身已包含新增债务、审批和四季度完成等交易风险。
检索:Supernus Indivior merger cost savings debt dividend regulatory approval risk
工具调用 · 历史记录,结果未知(7 种)
- list_mcp_resources · 结果未知
- stock_quote · 结果未知
- normalize_ticker · 结果未知
- kb_search · 结果未知
- price_snapshot · 结果未知
- search_case_library · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 1,484 字
Supernus Pharmaceuticals (SUPN.O) and Indivior Pharmaceuticals (INDV.O) said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions.
Shares of Supernus were up over 20% and Indivior shares were nearly 10% higher in premarket trading.
The combined company will have 11 marketed medicines for conditions including opioid addiction, epilepsy, migraine, Parkinson's disease and attention-deficit hyperactivity disorder. The companies expect about $125 million in annual cost savings.
Supernus shareholders will receive 1.5401 Indivior shares for each share held. Indivior shareholders will own about 56.5% of the combined company, while Supernus shareholders will hold the rest.
Indivior shareholders will also receive a $1 billion special cash dividend immediately before the merger closes. The companies plan to fund $650 million of the dividend with new debt and the rest with existing cash.
The combined company will be named Supernus, Inc and led by Supernus CEO Jack Khattar, the companies said. Together they are expected to have about $878 million in net debt.
The company will have an eight-member board that will include four directors from each company.
The merger is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals and other closing conditions.
Shares of Supernus were up over 20% and Indivior shares were nearly 10% higher in premarket trading.
The combined company will have 11 marketed medicines for conditions including opioid addiction, epilepsy, migraine, Parkinson's disease and attention-deficit hyperactivity disorder. The companies expect about $125 million in annual cost savings.
Supernus shareholders will receive 1.5401 Indivior shares for each share held. Indivior shareholders will own about 56.5% of the combined company, while Supernus shareholders will hold the rest.
Indivior shareholders will also receive a $1 billion special cash dividend immediately before the merger closes. The companies plan to fund $650 million of the dividend with new debt and the rest with existing cash.
The combined company will be named Supernus, Inc and led by Supernus CEO Jack Khattar, the companies said. Together they are expected to have about $878 million in net debt.
The company will have an eight-member board that will include four directors from each company.
The merger is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals and other closing conditions.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。